Diurnal Salivary Cortisol Profiles in Patients with Cushing’s Syndrome

Abstract

Background Quantification of salivary cortisol is one of the highly sensitive and specific screening parameters for Cushing’s syndrome (CS). However, only late-night salivary cortisol is part of the standard screening procedure. In this study, we aimed to analyze salivary cortisol day profiles in patients with different types of CS to test whether specific patterns might be relevant for diagnosis and subtyping.

Material and Methods Among 428 patients including those with confirmed Cushing’s syndrome (N=111, of those 75 with Cushing’s disease, 27 patients with adrenal CS and nine patients with ectopic CS), autonomous cortisol secretion (N=39) or exclusion of CS (control group, N=278) salivary cortisol was measured five times a day.

Results At each of the five time points, salivary cortisol was significantly higher in patients with CS compared to the control group (p≤0.001). Using the entire profile instead of one single salivary cortisol at 11 p.m. improved diagnostic accuracy (85 vs. 91%) slightly. Patients with ACTH-dependent CS had higher salivary cortisol levels than patients with adrenal CS. Also, morning cortisol was significantly higher in patients with ectopic CS than in patients with Cushing’s disease (p=0.04). Nevertheless, there was a strong overlap between diurnal profiles, and the diagnostic yield for subtyping was low.

Discussion The study results show that using diurnal salivary cortisol profiles for CS diagnosis results in a limited increase in diagnostic accuracy. With significant differences between Cushing subtypes, cortisol profiles are not useful in everyday clinical practice for subtyping of CS.

Key words

hypercortisolism - Cushing’s disease - circadian rhythm - adrenocorticotropin - pituitary - adrenal

Publication History

Received: 05 October 2021
Received: 25 November 2021

Accepted: 07 December 2021

Article published online:
17 January 2022

• References

• 1 Newell-Price J, Bertagna X, Grossman AB. et al. Cushing’s syndrome. Lancet (London, England) 2006; 367: 1605-1617 DOI: 10.1016/s0140-6736(06)68699-6.
• 2 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540 DOI: 10.1210/jc.2008-0125.
• 3 Reimondo G, Pia A, Bovio S. et al. Laboratory differentiation of Cushing’s syndrome. Clinica Chim Acta 2008; 388: 5-14 DOI: 10.1016/j.cca.2007.10.036.
• 4 Braun LT, Riester A, Osswald-Kopp A. et al. Toward a diagnostic score in Cushing’s syndrome. Front Endocrinol 2019; 10: 766 DOI: 10.3389/fendo.2019.00766.
• 5 Danet-Lamasou M, Asselineau J, Perez P. et al. Accuracy of repeated measurements of late-night salivary cortisol to screen for early-stage recurrence of Cushing’s disease following pituitary surgery. Clin Endocrinol 2015; 82: 260-266 DOI: 10.1111/cen.12534.
• 6 Amlashi FG, Swearingen B, Faje AT. et al. Accuracy of late-night salivary cortisol in evaluating postoperative remission and recurrence in Cushing’s disease. J Clin Endocrinol Metab 2015; 100: 3770-3777 DOI: 10.1210/jc.2015-2107.
• 7 Trilck M, Flitsch J, Lüdecke DK. et al. Salivary cortisol measurement-a reliable method for the diagnosis of Cushing’s syndrome. Exp Clin Endocrinol Diabetes 2005; 113: 225-230 DOI: 10.1055/s-2005-837667.
• 8 Castro M, Elias PC, Quidute AR. et al. Out-patient screening for Cushing’s syndrome: The sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84: 878-882 DOI: 10.1210/jcem.84.3.5521.
• 9 Laudat MH, Cerdas S, Fournier C. et al. Salivary cortisol measurement: A practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab 1988; 66: 343-348 DOI: 10.1210/jcem-66-2-343.
• 10 Berr CM, Di Dalmazi G, Osswald A. et al. Time to recovery of adrenal function after curative surgery for Cushing’s syndrome depends on etiology. J Clin Endocrinol Metab 2015; 100: 1300-1308 DOI: 10.1210/jc.2014-3632.
• 11 Berr CM, Stieg MR, Deutschbein T. et al. Persistence of myopathy in Cushing’s syndrome: Evaluation of the German Cushing’s Registry. Eur J Endocrinol 2017; 176: 737-746 DOI: 10.1530/eje-16-0689.
• 12 Braun LT, Fazel J, Zopp S. et al. The effect of biochemical remission on bone metabolism in Cushing’s syndrome: A 2-year follow-up study. J Bone Miner Res 2020; 35: 1711-1717 DOI: 10.1002/jbmr.4033.
• 13 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-g34 DOI: 10.1530/eje-16-0467.
• 14 Nieman LK. Cushing’s syndrome: Update on signs, symptoms and biochemical screening. Eur J Endocrinol 2015; 173: M33-M38 DOI: 10.1530/eje-15-0464.
• 15 Kosilek RP, Schopohl J, Grunke M. et al. Automatic face classification of Cushing’s syndrome in women – a novel screening approach. Exp Clin Endocrinol Diabetes 2013; 121: 561-564 DOI: 10.1055/s-0033-1349124.
• 16 Nugent CA, Warner HR, Dunn JT. et al. Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 1964; 24: 621-627 DOI: 10.1210/jcem-24-7-621.
• 17 Leon-Justel A, Madrazo-Atutxa A, Alvarez-Rios AI. et al. A probabilistic model for Cushing’s syndrome screening in at-risk populations: A prospective multicenter study. J Clin Endocrinol Metab 2016; 101: 3747-3754 DOI: 10.1210/jc.2016-1673.
• 18 Eisenhofer G, Masjkur J, Peitzsch M. et al. Plasma steroid metabolome profiling for diagnosis and subtyping patients with Cushing syndrome. Clin Chem 2018; 64: 586-596 DOI: 10.1373/clinchem.2017.282582.
• 19 Savas M, Wester VL, de Rijke YB. et al. Hair glucocorticoids as a biomarker for endogenous Cushing’s syndrome: Validation in two independent cohorts. Neuroendocrinology 2019; 109: 171-178 DOI: 10.1159/000498886.
• 20 Newell-Price J, Pivonello R, Tabarin A. et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease. Eur J Endocrinol 2020; 182: 207-217 DOI: 10.1530/eje-19-0695.
• 21 Yoshida K, Fukuoka H, Odake Y. et al. Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with Cushing’s syndromes treatment: Case presentations. Front Endocrinol 2017; 8: 375 DOI: 10.3389/fendo.2017.00375.
• 22 Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing’s disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985; 312: 1343-1349 DOI: 10.1056/nejm198505233122102.
• 23 Ikeda H, Abe T, Watanabe K. Usefulness of composite methionine-positron emission tomography/3.0-Tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg 2010; 112: 750-755 DOI: 10.3171/2009.7.jns09285.
• 24 Ritzel K, Beuschlein F, Berr C. et al. ACTH after 15 min distinguishes between Cushing’s disease and ectopic Cushing’s syndrome: A proposal for a short and simple CRH test. Eur J Endocrinol 2015; 173: 197-204 DOI: 10.1530/eje-14-0912.
• 25 Braun LT, Reincke M. What is the role of medical therapy in adrenal-dependent Cushing’s syndrome?. Best Pract Res Clin Endocrinol Metab 2020; 34: 101376 DOI: 10.1016/j.beem.2020.101376.
• 26 Debono M, Harrison RF, Chadarevian R. et al. Resetting the abnormal circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion. J Clin Endocrinol Metab 2017; 102: 3461-3469 DOI: 10.1210/jc.2017-00823.
• 27 Minnetti M, Hasenmajer V, Pofi R. et al. Fixing the broken clock in adrenal disorders: Focus on glucocorticoids and chronotherapy. J Endocrinol 2020; 246: R13-r31 DOI: 10.1530/joe-20-0066.